Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
| Autor: | Michael Federle, Judith Chezmar, Daniel L. Rubin, Jeffrey Weinreb, Patrick Freeny, Udo P. Schmiedl, Jeffrey J. Brown, Joseph A. Borrello, Joseph K.T. Lee, Richard C. Semelka, Robert Mattrey, Abraham H. Dachman, Sanjay Saini, Steven E. Harms, Donald G. Mitchell, Mark W. Anderson, Hollis H. Halford, William F. Bennett, Stuart W. Young, Matthew Rifkin, Spencer B. Gay, Rocco Ballerini, Paul F. Sherwin, Ronald O. Robison |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Cirrhosis MRI contrast agent Contrast Media Phases of clinical research Sensitivity and Specificity Diagnosis Differential Liver disease medicine Mangafodipir Humans Radiology Nuclear Medicine and imaging Medical diagnosis Edetic Acid Aged Aged 80 and over medicine.diagnostic_test business.industry Liver Neoplasms Magnetic resonance imaging Gold standard (test) Middle Aged Image Enhancement medicine.disease Magnetic Resonance Imaging Pyridoxal Phosphate Injections Intravenous Female Radiology business medicine.drug |
| Zdroj: | Journal of Magnetic Resonance Imaging. 12:689-701 |
| ISSN: | 1522-2586 1053-1807 |
| DOI: | 10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z |
| Popis: | The efficacy of contrast-enhanced magnetic resonance imaging (MRI) for detecting and characterizing, or excluding, hepatic masses was assessed in 404 patients, following the intravenous administration of mangafodipir trisodium (MnDPDP) injection, a hepatic MRI contrast agent. An initial contrast-enhanced computed tomography (CT) examination was followed by unenhanced MRI, injection of MnDPDP (5 μmol/kg IV), and enhanced MRI at 15 minutes post injection. Agreement of the radiologic diagnoses with the patients' final diagnoses was higher for enhanced MRI and for the combined unenhanced and enhanced MRI evaluations than for unenhanced MRI alone or enhanced CT using the clinical diagnosis as the gold standard. Mangafodipir-enhanced MRI uniquely provided additional diagnostic information in 48% of the patients, and patient management was consequently altered in 6% of the patients. MnDPDP-enhanced MRI was comparable or superior to unenhanced MRI and enhanced CT for the detection, classification, and diagnosis of focal liver lesions in patients with known or suspected focal liver disease. J. Magn. Reson. Imaging 2000;12:689–701. © 2000 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text